Publication
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Journal Paper/Review - Feb 2, 2010
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Units
PubMed
Doi
Citation
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
Type
Journal Paper/Review (English)
Journal
Br J Cancer 2010; 102
Publication Date
Feb 2, 2010
Issn Electronic
1532-1827
Pages
673-7
Brief description/objective
This analysis was initiated to define the predictive value of the area under the curve of high-dose methotrexate (AUC(HD-MTX)) in patients with primary central nervous system lymphoma (PCNSL).